cipramil (celexa) stories,, lundbeck, Newspaper and internet articles, psychiatry

The Lundbeck merry-go-round.

IFMAD
Click to view brochure

This November IFMAD are holding a symposium in Monte Carlo which is sponsored by an unrestricted grant from Lundbeck pharmaceuticals.

IFMAD is an abbreviation for ‘International Forum on Mood and Anxiety Disorders’ – an unfortunate abbreviation it has to be said. Their website is also sponsored by Lundbeck Pharmaceuticals.

According to their ‘Lundbeck sponsored’ website, IFMAD was founded in 2000 by ‘Professor Siegfried Kasper and Professor Stuart Montgomery’ and supported by a scientific committee from around the world.

So what, you may ask? What’s another pharma funded symposium? Why does it matter that the brochure has a huge advert for Lundbeck’s Cipralex/Lexapro? I dunno, you tell me, or maybe you could ask Brennan McCartney? No sorry, he’s dead, just because his doctor relied on the objectivity of the ‘experts’ advice, believed it, and subsequently prescribed Brennan a sample pack of Cipralex. You can read Brennan’s story here.

Coincidentally, both IFMAD founders, Siegfried Kasper (Austria) and Stuart A. Montgomery (UK), have previously ‘investigated’ Cipralex and both studies have had positive results here and here.

Irish Professor Timothy (Ted) Dinan is one of IFMADs scientific advisors, Again coincidentally, he is also a faculty member of the Lundbeck Institute here and a Lundbeck ‘Brain Explorer’ advisor, here. In fact Timothy et al also recently concluded a Cipralex study, this time in rodents, here. The first line states ‘Despite the clinical prevalence of the antidepressant escitalopram, over 30% of escitalopram-treated patients fail to respond to treatment’. Fairly objective statement you may think? In my opinion, that’s a very deceptive statement and expert spiel at its best. What it is actually saying is that Escitalopram (aka Cipralex/Lexapro) has clinical prevalence over other brands and that it works in almost 70% of cases.

Similarly, most of IFMAD’s scientific advisors (listed here), have participated in Cipralex studies and all (without exception) concluded positive results. Here’s a couple of examples: Christer Allgulander (Sweden) here, A.C Altamura (Italy) here, Michael Bauer (Germany) here and Naomi Fineberg (UK) here.

Again (Ahem) most likely coincidentally, at least 12 of IFMAD’s scientific advisors are also faculty members of the Lundbeck Institute: Dinan, Altamura, Boyer, Arango, Kennedy, Mendlewicz, Möller,  Papadimitriou, Rihmer, Stein, Vieta and Zohar.

Lars Von Knorring (Sweden) is an IFMAD scientific advisor. He lists Anne-Liis Von Knorring (relationship unknown) as one of his top co-authors here. She was the same professor who was accused of covering up the bad results of Lundbeck’s Celexa (same drug, different story) and actively misleading doctors and the public hereLars also did studies on Citalopram which once again proved positive; one example here.

Maybe I should get a life and forget that my son would be still alive if he didn’t take Citalopram (same drug as Cipralex), prescribed by doctors who believed in the ‘independent’ spiel dished out by ‘independent’ KOP’s (Key Opinion LiarsLeaders)? NO? You know what I think? I think that IFMAD is a Lundbeck creation, created to propagate the ‘independent’ KOP’s subjective pharma-funded belief in Lundbeck drugs. Yes IFMAD, IAM(VERYEFFING)MAD this lovely November morning! Lundbeck-funded propaganda at its worst.

Monte-Carlo (2002) here.

Monte-Carlo (2003) here.

Vienna (2005) here.

Vienna (2006) here.

Budapest (2007) here.

Vienna (2008) here.

Monaco (2009) here.

Vienna (2010) here.

Budapest (2011) here.

Barcelona (2012) here.

Monte Carlo (2013) here.